神经药理学报 ›› 2023, Vol. 13 ›› Issue (6): 45-.DOI: 10.3969/j.issn.2095-1396.2023.06.009

• 综述 • 上一篇    下一篇

阿尔茨海默症核心生物标志物及其他生物标志物研究进展

殷宏艳,尤斯涵,郭春燕   

  1. 河北北方学院药学院,河北省神经药理学重点实验室,张家口,075000,中国
  • 出版日期:2023-12-26 发布日期:2024-05-08
  • 通讯作者: 郭春燕,教授,硕士生导师;研究方向:体内药物分析和靶向药物分析;E-mail:guochy0311@163.com
  • 作者简介:殷宏艳,研究方向:药物分析;E-mail:3088850691@qq.com

Research Progress of Core Markers and Other Markers of Alzheimer's Disease

YIN Hong-yan, YOU Si-han, GUO Chun-yan   

  1. Department of Pharmacy, Hebei North University, Hebei Key Laboratory of Neuropharmacology, Zhangjiakou, 075000, China
  • Online:2023-12-26 Published:2024-05-08
  • Contact: 郭春燕,教授,硕士生导师;研究方向:体内药物分析和靶向药物分析;E-mail:guochy0311@163.com
  • About author:殷宏艳,研究方向:药物分析;E-mail:3088850691@qq.com

摘要:

阿尔茨海默症(Alzheimer's disease, AD)是一种神经退行性疾病,至今为止不能治愈。现存的主要诊断 方法是脑脊液中生物标志物的检测以及正电子发射式计算机断层扫描(positron emission computed tomography, PET),但由于其测试的侵入性和高成本,阻碍了临床实践中的应用。血液样本生物标志物由于其易得,价廉的特 点,有望可以实现AD 的早期诊断。该文总结了目前AD 常见的几种生物标志物以及它们在AD 患者中的变化, 并对未来AD 生物标志物的发展进行展望。

关键词: 阿尔茨海默症, 生物标志物, 脑脊液, 血液

Abstract:

Alzheimer's disease (AD) is a neurodegenerative disease that cannot be cured until now. The main existing diagnostic methods are the detection of biomarkers in cerebrospinal fluid and positron emission tomography (PET), but their application in clinical practice is hampered due to the invasiveness and high cost of their testing. Biomarkers in blood samples can make early detection and diagnosis of ad universal because of their easy availability and low price. This article summarizes several common biomarkers of AD and their changes in AD patients, and prospects the development of ad biomarkers in the future.

Key words: Alzheimer's disease, biomarkers, cerebrospinal fluid, blood